PSIP1 Antibody

Basic Research Questions

• What is PSIP1 and why is it significant in biomedical research?

  PSIP1, also known as LEDGF (Lens Epithelium-Derived Growth Factor) or DFS70, is a chromatin-associated and RNA-binding protein encoded by the PSIP1 gene in humans. This 530-amino acid residue protein functions as a transcriptional coactivator involved in neuroepithelial stem cell differentiation and neurogenesis. It is localized to the nucleus and widely expressed across multiple tissue types . PSIP1 has gained research significance due to its implications in cell survival, autoimmune diseases, HIV pathogenesis, and various cancer types, including breast, prostate, colon, and thyroid cancers . Its ability to regulate gene expression by modulating protein association with chromatin makes it a valuable target for studying transcriptional regulation mechanisms and potential therapeutic interventions.

• What are the main isoforms of PSIP1 and how do they differ functionally?

  PSIP1 exists in multiple isoforms, with the predominant ones being p75, p52, and p52 variant . The p75 isoform (also called LEDGF/p75) is the full-length protein and serves as a transcriptional coactivator. Research indicates that PSIP1/p75 specifically promotes cancer cell proliferation, while the p52 isoform may have distinct functions . These isoforms show differential expression patterns in various cell types and cancer tissues. For instance, basal-like breast cancer cell lines exhibit elevated levels of both p75 and p52 isoforms compared to normal mammary epithelial cells . When designing experiments, researchers should consider which specific isoform they aim to target, as this will influence antibody selection and experimental interpretations.

• What applications are PSIP1 antibodies commonly used for in research?

  PSIP1 antibodies are utilized in multiple research applications for antigen-specific immunodetection in biological samples. The most common applications include:

  • Western Blotting (WB): For protein expression quantification and molecular weight confirmation

  • Immunohistochemistry (IHC): For localization in tissue sections

  • Immunocytochemistry (ICC): For cellular localization studies

  • Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative protein detection

  • Immunoprecipitation (IP): For protein-protein interaction studies

  • Mass Spectrometry (MS): For protein identification and characterization

  Each application requires specific considerations regarding antibody selection, sample preparation, and optimization of experimental conditions to achieve reliable and reproducible results.

Methodological Considerations

• What factors should researchers consider when selecting a PSIP1 antibody for specific applications?

  When selecting a PSIP1 antibody, researchers should evaluate several critical factors:

  • Target epitope: Consider whether the antibody targets a specific isoform (p75 vs p52) or a common region

  • Host species: Select an antibody raised in a species different from the experimental sample to avoid cross-reactivity

  • Clonality: Monoclonal antibodies offer high specificity for a single epitope, while polyclonal antibodies provide broader recognition but potential cross-reactivity

  • Validated applications: Confirm the antibody has been validated for your specific application (WB, IHC, ICC, etc.)

  • Reactivity: Ensure the antibody recognizes PSIP1 in your species of interest (human, mouse, rat, etc.)

  • Conjugation: Determine if you need unconjugated antibody or one conjugated to fluorophores or enzymes

  • Published literature: Check for citations demonstrating successful use in similar experimental contexts

  For example, when studying PSIP1 in breast cancer tissues, researchers might select a rabbit polyclonal antibody that recognizes the amino acid region 301-530 of human PSIP1, which has been validated for both WB and IHC applications .

• How should researchers optimize sample preparation for PSIP1 detection in different applications?

  Sample preparation requirements vary significantly across different applications:

  For Western Blotting:

  • Use RIPA or NP-40 buffer with protease inhibitors for cell lysis

  • Include nuclear extraction steps since PSIP1 is predominantly nuclear

  • Denature samples at 95°C for 5 minutes in loading buffer containing SDS and DTT

  • Load 20-50 μg of total protein per lane

  For Immunohistochemistry:

  • Fix tissues in 10% neutral-buffered formalin

  • Use antigen retrieval methods (heat-induced epitope retrieval in citrate buffer pH 6.0)

  • Block endogenous peroxidase activity with hydrogen peroxide

  • Include epithelial cell markers when studying cancer tissues to distinguish PSIP1 expression in epithelial versus stromal components

  For Immunocytochemistry:

  • Fix cells with 4% paraformaldehyde

  • Permeabilize with 0.1% Triton X-100

  • Block with 5% normal serum from the same species as the secondary antibody

  • Include nuclear counterstain (DAPI) to confirm nuclear localization of PSIP1

• What controls should be included when working with PSIP1 antibodies?

  Proper controls are essential for validating PSIP1 antibody experiments:

  Positive controls:

  • Cell lines with known PSIP1 expression (e.g., MDA-MB231 or BT20 for high PSIP1 expression)

  • Recombinant PSIP1 protein (for Western blotting)

  Negative controls:

  • Isotype control antibody (same species and isotype as the primary antibody)

  • Tissues or cells with PSIP1 knockdown (using siRNA or shRNA)

  • Secondary antibody-only control (omitting primary antibody)

  • Blocking peptide competition (pre-incubating antibody with immunizing peptide)

  Additional validation:

  • Multiple antibodies targeting different PSIP1 epitopes should yield consistent results

  • Correlation with mRNA expression data

  • Verification of band size in Western blotting (expected molecular weights: p75 at ~75 kDa, p52 at ~52 kDa)

Advanced Research Applications

• How can researchers use PSIP1 antibodies to investigate its role in cancer progression?

  PSIP1 antibodies provide valuable tools for exploring PSIP1's role in cancer:

  Tumor tissue analysis:

  • Use IHC with PSIP1 antibodies on tissue microarrays (TMAs) to compare expression across different cancer stages and subtypes

  • Combine with infrared spectroscopic imaging for automated segmentation of tissue to differentiate epithelial PSIP1 expression from stromal components

  • Correlate PSIP1 expression with clinical outcomes using Kaplan-Meier survival analysis

  Mechanistic studies:

  • Perform chromatin immunoprecipitation (ChIP) using PSIP1 antibodies to identify gene promoters regulated by PSIP1

  • Use co-immunoprecipitation to identify PSIP1 protein interaction partners in cancer cells

  • Combine with isoform-specific knockdown (p75 vs p52) to determine isoform-specific functions

  Research shows that PSIP1 levels are significantly elevated in metastatic breast cancer samples compared to primary tumors, suggesting its involvement in metastatic progression . PSIP1/p75 specifically promotes cancer cell proliferation, making it a potential therapeutic target.

• What techniques can be used to differentiate between epithelial and stromal PSIP1 expression in tumor samples?

  Distinguishing epithelial from stromal PSIP1 expression is crucial for accurate interpretation of cancer tissue studies:

  • Infrared (IR) spectroscopic imaging: This advanced technique permits automated segmentation of tissue in conjunction with IHC. The molecular spectral data serves as a pattern to differentiate epithelial cells from stromal cells, allowing visualization of PSIP1 distribution specifically in epithelial cells

  • Dual immunofluorescence: Combine PSIP1 antibody with epithelial markers (cytokeratins, E-cadherin) or stromal markers (vimentin, α-SMA) using differently colored fluorophores

  • Laser capture microdissection: Physically separate epithelial from stromal components before analysis

  • Digital pathology: Use algorithms to classify tissue regions based on morphological features combined with IHC staining patterns

  Research has shown that when applying IR-IHC techniques to analyze matched patient samples from breast and lymph nodes, a significantly greater percentage of metastatic cancer cells stained positive for PSIP1 compared to invasive ductal carcinoma cells .

• What approaches are effective for studying PSIP1 isoform-specific functions?

  Investigating isoform-specific functions requires specialized techniques:

  • Isoform-specific antibodies: Use antibodies targeting unique regions of p75 (C-terminal region) or p52 (unique N-terminal region)

  • Selective knockdown: Design shRNAs targeting isoform-specific sequences (p75sh1 and p75sh2 for p75, p52sh for p52)

  • Rescue experiments: After knockdown, reintroduce individual isoforms to determine which restores specific functions

  • Domain mapping: Create deletion mutants to identify functional domains within each isoform

  • Chromatin immunoprecipitation sequencing (ChIP-seq): Compare genomic binding sites of different isoforms

  Research has demonstrated that selective depletion of PSIP1/p75 in triple-negative breast cancer cells significantly decreased migration, invasion, and tumorigenicity, while the p52 isoform may have distinct functions .

Troubleshooting and Quality Control

• How can researchers troubleshoot non-specific binding or false positives when using PSIP1 antibodies?

  Non-specific binding is a common challenge with antibody-based detection. To address this issue:

  • Optimize antibody concentration: Titrate primary antibody concentration to determine optimal signal-to-noise ratio

  • Modify blocking conditions: Increase blocking time/concentration or try different blocking agents (BSA, normal serum, commercial blockers)

  • Increase washing steps: Add additional washes with higher detergent concentration (0.1-0.3% Tween-20)

  • Validate specificity: Perform peptide competition assays or use PSIP1 knockout/knockdown samples as negative controls

  • Cross-validate with multiple antibodies: Use antibodies targeting different epitopes of PSIP1

  • Pre-adsorb antibody: Incubate with cell/tissue lysates from species with low homology to target

  • For IHC/ICC: Include antigen retrieval optimization and reduce secondary antibody concentration

  Researchers should note that PSIP1 antibodies might detect all three known isoforms (p75, p52, and p52 variant), which appear as distinct bands on Western blots . Additionally, other cell types like lymphocytes may be PSIP1-positive in tumor microenvironments, necessitating careful cell type identification .

• What strategies can improve detection of low-abundance PSIP1 in samples?

  For samples with low PSIP1 expression:

  • Signal amplification systems: Use tyramide signal amplification (TSA) or polymer-based detection systems for IHC/ICC

  • Protein concentration: Increase loaded protein amount for Western blotting or use immunoprecipitation to enrich PSIP1

  • Enhanced chemiluminescence: Use high-sensitivity ECL substrates for Western blot detection

  • Increase antibody incubation time: Extend primary antibody incubation to overnight at 4°C

  • Optimize exposure time: For Western blots, try multiple exposure times to capture weak signals

  • Alternative lysis methods: Ensure complete extraction of nuclear proteins where PSIP1 predominantly localizes

  • Fluorescence-based detection: Consider using fluorophore-conjugated secondary antibodies with sensitive imaging systems

  When analyzing patient samples, infrared spectroscopic imaging combined with IHC has proven effective for enhancing detection specificity of PSIP1 in epithelial cells even in complex tissue environments .

• How should researchers address discrepancies between PSIP1 antibody results and other detection methods?

  When facing conflicting results between antibody-based detection and other methods:

  • Verify antibody specificity: Confirm the antibody recognizes the intended PSIP1 isoform(s) using Western blot

  • Compare with mRNA data: Correlate protein expression with RT-qPCR data for PSIP1 transcripts

  • Consider post-translational modifications: Some antibodies may be sensitive to phosphorylation or other modifications

  • Evaluate detection limits: Different methods have varying sensitivity thresholds

  • Examine sample preparation differences: Protein extraction efficiency can vary between methods

  • Verify tissue/cellular localization: PSIP1 is predominantly nuclear, so cytoplasmic staining might indicate non-specific binding

  • Consider heterogeneity: Tissue heterogeneity may lead to sampling differences between methods

  Research shows that PSIP1 mRNA levels correlate with protein expression in many cases, but discrepancies can occur. For instance, PSIP1 mRNA levels in breast cancer don't always show stage-dependence, while protein levels might differ significantly between primary and metastatic samples .